

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Approximately what proportion of metastatic colorectal cancer (mCRC) cases are HER2 amplified?**
 - a. Less than 1%
 - b. 3% to 5%**
 - c. 25% to 30%
 - d. More than 50%
- 2. Which of the following proteins is targeted by adagrasib?**
 - a. HER2
 - b. EGFR
 - c. KRAS G12C**
 - d. NTRK
- 3. What was the approximate response rate for the HER2 IHC 1+ cohort of patients with mCRC in the Phase II DESTINY-CRC01 trial?**
 - a. 60%
 - b. 40%
 - c. 20%
 - d. 0%**
- 4. Fruquintinib inhibits which of the following targets?**
 - a. KRAS
 - b. VEGF**
 - c. PD-1
 - d. HER3
- 5. Which of the following statements best describes results of the Phase II ReDOS study evaluating standard dosing of regorafenib versus dose escalation for patients with refractory mCRC?**
 - a. No difference in the proportion of patients starting cycle 3 was observed between the study arms
 - b. More patients started cycle 3 in the dose-escalation arm**
 - c. More patients started cycle 3 in the standard-dose arm